Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation

PROCEPT BioRobotics received a positive outlook from Wall Street analyst Craig Bijou of Bank of America Securities, who maintained a Buy rating and $84 price target. Bijou believes the new Category I CPT code for Aquablation in the physician fee schedule will not significantly impact adoption, citing the procedure's impressive clinical results and standardization across prostate sizes. Bijou also notes that fees for Aquablation remain competitive with other procedures, ensuring urologists receive comparable compensation.

Procept BioRobotics (PRCT) has received a positive outlook from Wall Street analyst Craig Bijou of Bank of America Securities, who maintained a Buy rating and $84 price target. Bijou believes the new Category I CPT code for Aquablation in the physician fee schedule will not significantly impact adoption, citing the procedure's impressive clinical results and standardization across prostate sizes. Bijou also notes that fees for Aquablation remain competitive with other procedures, ensuring urologists receive comparable compensation.

The new Category I CPT code for Aquablation therapy, effective January 1, 2026, is expected to enhance its recognition and acceptance in the medical community, marking a significant advancement for Procept BioRobotics. The new CPT code, 52XX1, replaces the previous Category III code and is associated with a proposed payment rate of approximately $540 under Medicare, slightly higher than the payment for traditional TURP procedures. This change is expected to support surgeon adoption and broaden patient access to Aquablation therapy [3].

Leerink also finds the recent increase in the payment rate for Aquablation procedures under the Centers for Medicare & Medicaid Services’ (CMS) proposed OPPS rule for 2026 to be significant. The payment rate will increase to approximately $9,765, up from $9,247, marking a 5.6% rise year-over-year. Leerink remains optimistic about the risk and return potential for Procept, retaining an Outperform rating ahead of the upcoming Q2 earnings report and beyond [1].

Based on the one-year price targets offered by 10 analysts, the average target price for PROCEPT BioRobotics Corp (PRCT) is $77.20, with a high estimate of $90.00 and a low estimate of $60.00. The average target implies an upside of 33.08% from the current price of $58.01. The consensus recommendation from 13 brokerage firms is currently 1.9, indicating "Outperform" status [1].

Procept BioRobotics focuses on developing transformative solutions in urology, particularly its AquaBeam Robotic System and HYDROS Robotic System. The company's products aim to treat benign prostatic hyperplasia (BPH) using image-guided, surgical robotic systems. Procept BioRobotics was incorporated in 2007 and is headquartered in San Jose, California [2].

References:
[1] https://www.gurufocus.com/news/2981325/procept-biorobotics-prct-gains-from-medicares-favorable-decision-prct-stock-news
[2] https://finance.yahoo.com/quote/PRCT/
[3] https://www.nasdaq.com/articles/procept-biorobotics-announces-category-i-cpt-code-assignment-aquablation-therapy-effective